CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04603365
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:09.840065+00:00
Published At: 2023-05-17T00:00:00+00:00
Record Updated At: 2023-05-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Clear Cell Papillary Renal Neoplasm", "Collecting Duct Carcinoma", "Hereditary Leiomyomatosis and Renal Cell Carcinoma", "Hereditary Papillary Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Unclassified Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8", "Stage IV Renal Cell Cancer AJCC v8", "Tubulocystic Renal Cell Carcinoma", "Unresectable Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-05-17"
protocolSection.identificationModule.nctId: "NCT04603365"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.